Pfizer and BioNTech received FDA approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant, covering adults 65 and older plus high-risk individuals ages 5-64. More than five billion COMIRNATY doses have been distributed globally, with shipping beginning immediately across U.S. pharmacies, hospitals and clinics.
Pfizer and BioNTech received FDA approval for their XFG-targeted COVID-19 vaccine, with more than five billion COMIRNATY doses distributed globally.
The supplemental Biologics License Application approval follows FDA guidance issued in May selecting XFG as the preferred vaccine composition for the U.S. beginning in fall 2026, the companies said in a joint statement.
The 2026-2027 formula is approved for adults ages 65 and older, plus individuals ages 5 through 64 with at least one underlying condition that puts them at high risk for severe COVID-19 outcomes. The approval draws on clinical, non-clinical and real-world data showing strong immune responses against circulating variants including XFG, XFG.1.1, NB.1.8.1, PQ.17 and PQ.2.8.1.
Shipping begins immediately, with doses reaching pharmacies, hospitals and clinics across the U.S. in the coming days. Pfizer shares fell 0.99 percent and BioNTech dropped 1.03 percent on the announcement. The approval locks in a revenue stream for both companies for the 2026-2027 season, with BioNTech serving as marketing authorization holder in the U.S., EU, UK and other markets.
The approval extends the companies' position in the mRNA vaccine market, where they compete with Moderna's Spikevax. Moderna has not yet received FDA approval for its own 2026-2027 formula targeting the XFG variant, leaving Pfizer and BioNTech with a potential first-mover advantage in the fall vaccination campaign.
COMIRNATY continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, pharmacovigilance and manufacturing data, the companies said. The vaccines are based on BioNTech's proprietary mRNA technology and were developed jointly by both companies, with BioNTech holding marketing authorization in the U.S., EU, UK and other jurisdictions.
The FDA's selection of the XFG variant reflects the regulator's effort to more closely match contemporary circulating SARS-CoV-2 lineages. The approval aligns with the agency's guidance on vaccine composition for the upcoming season, and the companies said the adapted vaccine generated strong immune responses against multiple contemporary lineages in non-clinical studies. The XFG variant has become the dominant circulating lineage in the U.S., according to the companies.
The approval gives Pfizer and BioNTech a competitive advantage in the fall vaccination season, with immediate shipping providing a first-mover position over rivals. Investors will watch uptake rates and government purchasing decisions for the 2026-2027 season as key indicators of revenue impact for both companies.
This article is for informational purposes only and does not constitute investment advice.
